About this trial
Histopathology remains the gold standard for disease diagnosis, yet faces challenges including pathologist shortages and diagnostic model limitations. This underscores the critical need to develop deep learning-based pathology foundation models integrating prospective imaging and clinical data. Such models would enhance diagnostic accuracy and efficiency, enabling tumor grading, histo-molecular classification, and intelligent chemotherapy guidance - ultimately optimizing clinical workflows. However, a critical gap remains: the absence of prospectively validated, pan-disease pathology foundation models. Developing clinically validated models is therefore imperative.
Eligibility criteria
Qualifiers
Aged 18-75 years old.
Patients with complete pathological slides and clinical information.
Disqualifiers
None
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Sponsors and collaborators
Nanfang Hospital, Southern Medical University
Lead sponsor
Qianfoshan Hospital
Collaborator
Zhejiang University
Collaborator
The First Affiliated Hospital of Zhengzhou University
Collaborator
First Affiliated Hospital of Shantou University Medical College
Collaborator
Zhujiang Hospital
Collaborator
Air Force Military Medical University, China
Collaborator